GLP-1 Coverage Shifts in Employee Health Plans

The landscape of coverage for glucagon-like peptide-1 receptor agonists (GLP-1s) within employee health plans is shifting, with companies like Cigna and PepsiCo re-evaluating their commitments due to rising costs.

Many companies are reassessing their insurance strategies in light of the high costs associated with GLP-1 medications, used both for weight loss and diabetes management. Cigna announced it would no longer offer coverage for GLP-1s specifically for weight loss within its employee health plans as of July 1. Similarly, PepsiCo discontinued GLP-1 coverage for weight loss due to cost concerns, although they maintain coverage for diabetes care. These decisions reflect a growing trend as employers balance comprehensive healthcare against sustainable costs.

Market Trends and Regulatory Context

The popularity of GLP-1 medications has surged, especially following FDA approvals of Wegovy in 2021 and Zepbound in 2023. This increase in prescriptions signals a significant market shift: approximately 11% of U.S. adults now use GLP-1s for weight loss, a notable rise from 3% in prior years, as reported by Gallup. Despite their effectiveness in weight and cardiovascular risk reduction, these drugs come at substantial costs. A KFF study highlights how increased usage rates raise prescription expenses, driving some employers to reconsider coverage offerings.

Cost Implications for Employers

Employers like PepsiCo have noted the rapid cost escalation of prescription weight loss medications in their healthcare plans, prompting coverage withdrawal as a sustainability measure. The financial burden is evident, with costs ranging from as low as $25 to over $1,000 per month based on insurance and specific medications like Eli Lilly’s Zepbound. Although beneficial, the price of GLP-1s makes their coverage a contentious issue, especially as companies evaluate employee health benefits versus economic pressures.

Medication Costs at a Glance

Broader Industry Considerations

Decisions on GLP-1 coverage are complex, influenced by factors beyond cost. Paul Fronstin from the Employee Benefit Research Institute suggests these are multifaceted business choices involving long-term benefits versus immediate expenses. While some companies push for cost-sharing moderation, others might reintroduce coverage if drug prices decrease. In contrast, companies like Bank of America continue GLP-1 coverage, valuing its role in employee health and retention strategies.

Moreover, smaller businesses may rely on health plans to navigate these decisions, potentially leading to diverse coverage landscapes. As research into the impacts of coverage termination on patient health continues, the industry watches closely for developments that may reshape these strategies. This situation underscores the need for a balanced approach to managing healthcare benefits, ensuring both cost-effectiveness and employee well-being are well-considered.